Olga Shestova
Overview
Explore the profile of Olga Shestova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
3960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, et al.
Cancer Cell
. 2025 Feb;
43(3):537-551.e7.
PMID: 39983725
Tumor resistance to chimeric antigen receptor T cell (CAR-T) and, in general, to adoptive cell immunotherapies (ACTs) is a major challenge in the clinic. We hypothesized that inhibiting the tumor...
2.
Reiss K, Angelos M, Dees E, Yuan Y, Ueno N, Pohlmann P, et al.
Nat Med
. 2025 Feb;
PMID: 39920391
Chimeric antigen receptor (CAR) macrophages (CAR-Ms) mediate antitumor immunity via phagocytosis, cytokine release, activation of the tumor microenvironment and antigen presentation. We report results from a non-prespecified interim analysis of...
3.
Pierini S, Gabbasov R, Oliveira-Nunes M, Qureshi R, Worth A, Huang S, et al.
Nat Commun
. 2025 Jan;
16(1):706.
PMID: 39814734
We previously developed human CAR macrophages (CAR-M) and demonstrated redirection of macrophage anti-tumor function leading to tumor control in immunodeficient xenograft models. Here, we develop clinically relevant fully immunocompetent syngeneic...
4.
Bhagwat A, Torres L, Shestova O, Shestov M, Mellors P, Fisher H, et al.
Nat Med
. 2024 Sep;
30(12):3697-3708.
PMID: 39333315
Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in AML has not recapitulated the...
5.
Patel R, Ghilardi G, Zhang Y, Chiang Y, Xie W, Guruprasad P, et al.
Sci Immunol
. 2024 Jul;
9(97):eadn6509.
PMID: 39028827
Most patients treated with US Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid...
6.
Veliz K, Shen F, Shestova O, Shestov M, Shestov A, Sleiman S, et al.
Mol Ther Oncol
. 2024 Jun;
32(2):200819.
PMID: 38912091
Cell surface molecules transiently upregulated on activated T cells can play a counter-regulatory role by inhibiting T cell function. Deletion or blockade of such immune checkpoint receptors has been investigated...
7.
Guruprasad P, Carturan A, Zhang Y, Cho J, Kumashie K, Patel R, et al.
Nat Immunol
. 2024 Jun;
25(6):1020-1032.
PMID: 38831106
The efficacy of T cell-based immunotherapies is limited by immunosuppressive pressures in the tumor microenvironment. Here we show a predominant role for the interaction between BTLA on effector T cells...
8.
Glisovic-Aplenc T, Diorio C, Chukinas J, Veliz K, Shestova O, Shen F, et al.
Blood Adv
. 2023 May;
7(16):4418-4430.
PMID: 37171449
Many hematologic malignancies are not curable with chemotherapy and require novel therapeutic approaches. Chimeric antigen receptor (CAR) T-cell therapy is 1 such approach that involves the transfer of T cells...
9.
Lu C, Glisovic-Aplenc T, Bernt K, Nestler K, Cesare J, Cao L, et al.
J Proteome Res
. 2021 Oct;
20(11):5203-5211.
PMID: 34669412
With the rapid developments in mass spectrometry (MS)-based proteomics methods, label-free semiquantitative proteomics has become an increasingly popular tool for profiling global protein abundances in an unbiased manner. However, the...
10.
Singh N, Frey N, Engels B, Barrett D, Shestova O, Ravikumar P, et al.
Nat Med
. 2021 Apr;
27(5):842-850.
PMID: 33888899
While CD19-directed chimeric antigen receptor (CAR) T cells can induce remission in patients with B cell acute lymphoblastic leukemia (ALL), a large subset relapse with CD19 disease. Like CD19, CD22...